Pfizer's (PFE) disclosure in a quarterly 10-Q filing with the SEC that it is under investigation in Germany over "tax matters" and "improper payments" in other foreign countries isn't news, even ...

Pfizer reached a record $100 billion in revenue last year, thanks to its coronavirus portfolio. But a decline in vaccine demand and competition ahead for some of Pfizer’s other top products is set to ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for ...

A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the ...

With thousands of lawsuits and growing concerns over long-term risks, the FDA have added brain tumor warning to the label.

LONDON (Reuters) - European Commission President Ursula von der Leyen’s silence about her dealings with drugmaker Pfizer leading to the EU's biggest COVID-19 vaccine contract is hurting public trust ...

When a big pharmaceutical company blazes a path with a new product, it often makes it easier for competitors to introduce their own version. MannKind Inc. is finding it cuts the other way, too. Pfizer ...

LONDON (Reuters) - Biotech stocks advanced in Europe on Monday as the failure of Pfizer Inc's experimental drug torcetrapib highlighted pipeline problems at big pharma firms, which are expected to ...

Pfizer (NYSE: PFE) brought in more than $100 billion in revenue last year -- a record. But investors know it may be difficult for the pharmaceutical giant to reach that level again anytime soon.